Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease

NCT07671222 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Sjogren Syndrome
Sjogren Syndrome With Keratoconjunctivitis
Dry Eye Disease (DED)

Interventions

DRUG: Infliximab 0.1%
DRUG: Loteprednol

Sponsor

Instituto de Oftalmología Fundación Conde de Valenciana